Discover 1,248 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Nashville offers many research opportunities for conditions such as diabetes, cardiovascular disease, and arthritis, giving participants access to innovative treatments and cutting-edge medical care. The city’s leading healthcare institutions are actively recruiting healthy volunteers for paid research studies, as well as individuals seeking trials for specific health concerns.
Filter
2
Filter results
Results: 1,248
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
for
Solid Tumors, Hematologic Malignancies
Location: Nashville TN, Omaha NE, Houston TX, Duarte CA
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT07195916
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
for
Breast Cancer
Location: Nashville TN, Salem VA, Columbia MD, Norfolk VA,
Sponsor: SCRI Development Innovations, LLC
Sex: All
Age: 18+
Code: NCT05748834
Phase2, Recruiting
SMP-3124LP in Adults With Advanced Solid Tumors
for
Solid Tumor
Location: Nashville TN, Denver CO, Columbus OH, Chicago IL,
Sponsor: Sumitomo Pharma America, Inc.
Sex: All
Age: 18+
Code: NCT06526819
Phase1, Phase2, Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
for
Ovarian Cancer, Solid Tumor
Location: Nashville TN, Denver CO, Grand Rapids MI, Fairfax VA,
Sponsor: OnCusp Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06234423
Phase1, Recruiting
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
for
Advanced Solid Tumor, Metastatic Solid Tumor
Location: Nashville TN, Denver CO, Durham NC, Fairfax VA,
Sponsor: Jazz Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06108050
Phase1, Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
for
Melanoma, Cutaneous Malignant
Location: Nashville TN, Columbus OH, Chicago IL, Chapel Hill NC,
Sponsor: Immatics US, Inc.
Sex: All
Age: 18+
Code: NCT06743126
Phase3, Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
for
Colorectal Neoplasms
Location: Nashville TN, Atlanta GA, Jonesboro AR, St Louis MO,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06662786
Phase3, Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)